Don Hutson
Footballguy
Last edited by a moderator:
Link is no good. What's the details?Philippines
http://themanilapost.net/chiral-pharma-cytodyn-inc-partners-to-secure-covid-19-drug-fda-approval/Link is no good. What's the details?
You need to update your subscription to the Manila Post. I can't believe you let it run out!Link is no good. What's the details?
EDIT: NM Looks like they've hired someone to apply for approval in PHIL
https://www.globenewswire.com/news-release/2020/10/13/2107107/0/en/CytoDyn-Appoints-Chiral-Pharma-to-Secure-Leronlimab-for-Local-FDA-Approval-in-Philippines.html
What means this?Very minor mildly interesting (to me) number-
held my institution went from .0373 to .0432
also could mean nothing
Ouch. Self esteem just took a dump....No one important owns the stock
Not sure but the watermark suggests perhaps not?
Why would some offer 2B when the can buy the rights to LL and the"$58k" in used printers and coffee makers on the courthouse steps.Seems like more good news for the long-term. Hoping for a buyout.
https://academic.oup.com/rev/pages/PoliciesNot sure but the watermark suggests perhaps not?
That must be the reason they had to push the call back an hour.Our boy is on fox business right now
There are like 20 people who post regularly on that board. It ranges from insane pumpers to equally insane shorts. I hate them all.Anybody going to listen to the CC? Hard to get any info from the yahoo board as they are all insane pumpers.
Doesn't sound like there was a pause so this isn't right. They are just slowly enrolling right now.The S/C trial seems to have been halted since at least September 30th. When there were questions whether HGEN would do an interim analysis, Dr Javitt said they wouldn't do one because they would have to halt the trial for a month while it happened. So maybe CytoDyn was forced to halt it to do the interim analysis.
Yeah, when Dr Seethamraju said there were 221 patients enrolled in his October 7th presentation, he must have been using enrollment numbers that hadn't been updated. I wonder if enrollment slowed because they were hoping for an EUA or if it was because no one was asking for it? On September 10th, there were 210 patients enrolled. So there have been 20 patients enrolled in the last 40 days. At that pace, the S/C trial won't get to 293 patients for 4 more months and won't get to 390 patients for 10 more months. Hopefully, UK trial sites starting up will speed enrollment. If UK sites don't start, people will be forced to try leronlimab at some point this winter when other treatments run out of product which could happen sooner rather than later with the way Covid numbers are spiking.Doesn't sound like there was a pause so this isn't right. They are just slowly enrolling right now.
When is HGEN trial completing?Yeah, when Dr Seethamraju said there were 221 patients enrolled in his October 7th presentation, he must have been using enrollment numbers that hadn't been updated. I wonder if enrollment slowed because they were hoping for an EUA or if it was because no one was asking for it? On September 10th, there were 210 patients enrolled. So there have been 20 patients enrolled in the last 40 days. At that pace, the S/C trial won't get to 293 patients for 4 more months and won't get to 390 patients for 10 more months. Hopefully, UK trial sites starting up will speed enrollment. If UK sites don't start, people will be forced to try leronlimab at some point this winter when other treatments run out of product which could happen sooner rather than later with the way Covid numbers are spiking.
They aren't as specific with updates or promises as CYDY. Originally, I thought enrollment was supposed to complete at the end of September. In this October investor presentation, they say that the phase III enrollment is over 50% and that full enrollment and top line data results are expected in Q4 of 2020. For topline data results to be released by the end of December, enrollment would have to conclude by mid-November at the latest.When is HGEN trial completing?
Couldn’t make the call. Was there anything else of note, good or bad. Was up listing mentioned at all? ThxNothing from the Night King yet, usually he would have found something to lay into by now.
The BLA for HIV timeline still seems vague to me even though NP keeps saying 100% they will be approved. Odd behavior.
Overall this seems like a decent day for CYDY though. Just on time for me to reevaluate if I want to buy back some of what i sold. Im going to be patient.
CytoDyn Investors Sell Despite Positive Recommendation From DSMB And A More Certain Path To COVID-19 Approval
https://talkmarkets.com/content/stocks--equities/cytodyn-investors-sell-despite-positive-recommendation-from-dsmb-and-a-more-certain-path-to-covid-19-approval?post=282160
The news was pretty much what I was expecting. Trial continues to completion.Couldn’t make the call. Was there anything else of note, good or bad. Was up listing mentioned at all? Thx
Thx for the recap!The news was pretty much what I was expecting. Trial continues to completion.
As far as what else was good or bad, kind of debatable. The things that I'm concerned with I'm still concerned with. Would like to see some government backing, would like to know if another country is seriously interested and I don't really have answers to those questions. No imminent timeline for the HIV BLA so no idea when that completes. Not sure how quickly they can fill the phase 3 trial for Covid so we could be well into 2021 before we have it complete. Uplisting to Nasdaq I didn't hear about but pretty sure nothing anytime soon.
On the plus note, Doctors are starting to get published although unclear if peer reviewed (i don't think so). They will have another review before the trial completes. They didn't halt the trial so Leronlimab is obviously doing enough of merit to warrant finishing. It's probably not a home run but it may still be helpful IMO
Opens with a straight out lie..."I don't know if Trump received this treatment". Ummm...yes you would know because your drug is sitting in the break room fridge getting stale and not at the local pharmacy.
David Assman: This is one of the drugs that President Trump received?Opens with a straight out lie..."I don't know if Trump received this treatment". Ummm...yes you would know because your drug is sitting in the break room fridge getting stale and not at the local pharmacy.
Hahaha, I thought for sure you were making this up so had to watch. I can't believe this is a real exchange.David Assman: So this is derived from the blood of those who have had Covid?
Nader: No, it comes from mouse
The interviewer should be put out to pasture for opening up with that garbage. I think that one even surprised Nader, he didn't have an answer teed up. Think he did fine given that oddball intro.Opens with a straight out lie..."I don't know if Trump received this treatment". Ummm...yes you would know because your drug is sitting in the break room fridge getting stale and not at the local pharmacy.
Harvard? Not impressed. If he was from App State, then I would be excited.Dr. Rahman's credentials (new Chief Scientific Officer):
-Harvard Professor of Medicine
-Johnson & Johnson: Senior Director Clinical Research & Development
-Pfizer: VP Medical Affairs
-Novartis: VP Global Clinical Development
-Glenmark Pharmaceuticals: President & CMO
-Mesoblast: Global Head Immunology Development
Well nowDr. Rahman's credentials (new Chief Scientific Officer):
-Harvard Professor of Medicine
-Johnson & Johnson: Senior Director Clinical Research & Development
-Pfizer: VP Medical Affairs
-Novartis: VP Global Clinical Development
-Glenmark Pharmaceuticals: President & CMO
-Mesoblast: Global Head Immunology Development
Paging Don Hutson.Dr. Rahman's credentials (new Chief Scientific Officer):
-Harvard Professor of Medicine
-Johnson & Johnson: Senior Director Clinical Research & Development
-Pfizer: VP Medical Affairs
-Novartis: VP Global Clinical Development
-Glenmark Pharmaceuticals: President & CMO
-Mesoblast: Global Head Immunology Development
Maybe the cynic in you should actually be saying why does he keep washing out everywhere to finally end up here.Those are the type of things that keep me invested and believing in the stock.